IL13 and chronic obstructive pulmonary disease: Nevertheless, cytokine blockade is a novel treatment strategy, and several monoclonal antibodies are being evaluated for COPD treatment, including dupilumab (anti-IL4), reslizumab and benralizumab (anti-IL5), and lebrikizumab and tralokinumab (anti-IL13) [20].